Bliss GVS Pharma: The unaudited standalone and consolidated financial results for the quarter and half year ended September…

What happened

Bliss GVS Pharma (BLISSGVS) filed a disclosure with the exchanges on 29 October 2026 at 05:00 PM titled "The unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026".

Company snapshot

Bliss GVS Pharma is a small-cap company, with a market value of about ₹7,221 crore.

The stock last traded at ₹680.9, against a 52-week range of ₹118–₹739.9 (8.0% below the high).

Before this filing the shares had moved −8.0% over the month and +42.2% over three months. Average daily turnover over the last 20 sessions was about ₹11.88 crore.

Promoters held 35.01% at the end of Q1 FY27, down 0.35% points from the previous quarter. Foreign institutions owned 8.07% and domestic institutions 9.47%.

What history shows

BCEIE has no earlier results filing from this company on record since May 2026.

Market-wide, 9,836 results filings with an impact score of 50 or more saw an average next-day move of −0.3%, with 42% rising.

Past reactions describe what happened before; they are not a forecast.

What to watch

• Management commentary, margins and order book or guidance in the investor presentation.
• 29 October 2026: Board meeting — Financial Results/Other business matters.

In the news

Recent coverage elsewhere (links open the original publisher):

• Anupam Rasayan revises Bliss GVS open offer timeline, IDC recommends tender — scanx.trade, 18 Oct 2026
• Anupam Rasayan India acquires controlling stake in Bliss GVS Pharma; Kanga & Co advises sellers — Bar and Bench, 28 Oct 2026
• We Ran A Stock Scan For Earnings Growth And Bliss GVS Pharma (NSE:BLISSGVS) Passed With Ease — Simply Wall St, 22 Oct 2026
• Bliss GVS Pharma BLISSGVS Postal Ballot Notice October 2026 — Kalkine India, 16 Oct 2026
• Bliss GVS Pharma seeks shareholder approval for three new directors — scanx.trade, 29 Oct 2026

Source

• Exchange filing (PDF)